IFW

JUN ? 5 2007 IN THE UNITED STATES PATENT AN In Flaton Application of: Hideki SHIMADA et al.	Docket No.: 1254-0326PUS1 (PATENT) D TRADEMARK OFFICE			
Application No.: 10/594,771	Confirmation No.: 6731			
Filed: September 29, 2006	Art Unit: N/A			
For: DIAGNOSTIC KIT FOR SOLID CANCER AND MEDICAMENT FOR SOLID CANCER THERAPY	Examiner: Not Yet Assigned			
RESPONSE TO NOTIFICATION OF PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES				

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Containing Nucleotide and/or Amino Acid Sequence Disclosures dated April 23, 2007,

In response to the Notification to Comply with Requirements for Patent Applications

therewith.

Ĩ	Appı	leation No.: 10/594,771 Docket No.: 1254-0326PUS1
- T		The undersigned hereby declares that "Attorney Docket No. 1254-0326PUS1" on page 1 of the attached Inventors' Declaration corresponds to Appl. No. 10/594,771 filed September 29, 2006 entitled "DIAGNOSTIC KIT FOR SOLID CANCER AND MEDICAMENT FOR SOLID CANCER THERAPY."
		Attached is an English language translation of the above-identified application that was filed in a foreign language, which should be used as the copy for examination purposes.
		See the attached Translator's Verification; or
		The undersigned states that the English translation attached hereto is a true and correct translation of the application as originally filed in a foreign language.
		Attached are 0 sheet(s) of drawings. Please substitute these replacement drawings for the corresponding 0 sheet(s) of drawings on file in the above-identified application.
		Attached are substitute claims commencing on a separate sheet in accordance with 37 C.F.R. § 1.75(h).
		Attached is a substitute abstract commencing on a separate sheet in accordance with 37 C.F.R. § 1.72(b).
		Attached is a substitute specification that complies with 37 C.F.R. § 1.52. The substitute specification does not contain new matter.
	\boxtimes	Attached is an Amendment.
		Applicant claims small entity status under 37 C.F.R. § 1.27.
	\boxtimes	Attached is a Sequence Listing. (Disk and Paper Copies)
•		Submitted concurrently herewith under separate cover for recording is an Assignment.
		Attached is a Petition for Extension of Time.

Application No.: 10/594,771 Docket No.: 1254-0326PUS1 The Government Filing Surcharge for late filing of oath and/or declaration in the amount of \$130.00 in accordance with 37 C.F.R. §§ 1.494 and 1.492 was previously paid for concurrently with the filing of the application on September 29, 2006. Attached hereto is the fee transmittal listing the required fees. If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated:

JUN 2 5 2007

Respectfully submitted,

Registration No. 28,977

BIRCH, STEWART, KOLASOH & BIRCH, LLP

8110 Gatehouse Road Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

Attachments- Amendment

Sequence Listing (Disk and Paper Copies)

03/29/2004



amm

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Ext 1450 Ainxandria, Virginia 22313-1450

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

10/594,771 Hideki Shimada 1254-0326PUS1

INTERNATIONAL APPLICATION NO.

PCT/JP05/06222

LA. FILING DATE PRIORITY DATE

2292 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747 DOCKETED Jeguera listing 10.23.2007

CONFIRMATION NO. 6731 371 FORMALITIES LETTER

03/24/2005

Date Mailed: 04/23/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

• For Rules Interpretation, call (571) 272-0951

ŧ

- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/594,771	РСТ/ЈР05/06222	1254-0326PUS1

FORM PCT/DO/EO/922 (371 Formalities Notice)